



Express Mail No.: EL 265 830 890 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Murphy et al.

Application No.: 09/016,737

Group Art Unit: 1642

Filed: January 30, 1998

Examiner: Y. Eyler

For: ISOLATION AND/OR
PRESERVATION OF DENDRITIC
CELLS FOR PROSTATE CANCER
IMMUNOTHERAPY

Attorney Docket No.: 8511-007

RESPONSE UNDER 37 C.F.R. §1.111

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
JUL 16 1999
TC 1600 MAIL ROOM

Sir:

In response to the outstanding Office Action, dated June 4, 1999, please consider the following remarks. Submitted herewith is a Petition for an Extension of Time to Respond for one month to and including August 4, 1999, together with the necessary fee.

REMARKS

Restriction to one of the following has been required under 37 U.S.C. §121:

Group I, Claims 1-12, directed to a method of treatment of prostate cancer by administration of T cells;

Group II, Claims 13-22, directed to a method of treatment of prostate cancer by administration of dendritic cells; and

Group III, Claims 23-30, directed to a composition comprising dendritic cells.

Further, the Office Action asserts that whichever Group is elected, election of a single species must be made, said election selected from:

(a) antigens and sequences derived from prostate cell lysates;